Avacta Share Discussion Threads

[bumpa33] 08/1/2019 11:29

very impressive presentation actually, i've just listened through it again. Critical for me here is the work of Affimers as a targeted drug delivery platform, across a whole field of therapeutics, rather than merely a specific/single drug. The potential is truly enormous, especially with just a couple of competitors - Ablynx having been taken over. And then there is the backup of the diagnostics business. The wider market surely has to wake up to this sooner or later.

[cf456] 08/1/2019 11:10

No probs.

Another positive here is that the company is fully cashed up for the forseeable. With so many AIM stocks there is the constant worry of a placing in the short term, but AVCT has plenty of cash.

Capital Network - "After the recent fundraising the company is well funded for the next 18-24 months".

Hardman & Co. - "AVCT has sufficient cash resources to identify an Affimer lead to be ready for first-in-man trials in 2020"

Additionally, the recent LG Chem deal will provide useful near term cash.

And of course multiple further deals are expected, each of which will potentially add yet further cash.

[hampton58] 08/1/2019 11:01

Speaking of SanofiRegeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs.However I note Libtayo is unaffected.The companies' ongoing collaboration for the development and commercialization of Libtayo® (cemiplimab-rwlc), a PD-1 antibody, is unaffected by the amended Discovery and Development Agreement.All the majors are in SF and so are the Biotech community/Private Equity/ Peer Group Keep an eye on the news flow over the next day or so

[bumpa33] 08/1/2019 10:59

very interesting presentation cf456, thanks for posting.

14.15 very pertinent point...

[hampton58] 08/1/2019 10:22

Immune oncology one of the hottest areas at the moment and more M&A to be expected.One of the key panel discussions at the Biotech Showcase in SF this week.More license deals to be expected.Share price ridiculously low

[cf456] 08/1/2019 10:21

Comparatives from the CEO at the Turner Pope presentation certainly highlight significant potential upside from the current valuation. He reckons 18 months to get the tech to the level of Pieris which had a £220m valuation at the time of the presentation.

"Pieris, Nasdaq-listed, has drugs in Phase 1/Phase 2, so really only 18 months or so away from where we are and yet there's a roughly 10x increase in valuation."

- from 16:52

[bumpa33] 08/1/2019 10:17

Mkt cap is paltry considering even just the first part of the LG Chem deal - the funds it will bring and as importantly, the validation of Affimers in immuno-oncology. Fair value has to be at least the mid 40’s, here and now. Going forward, well heaven only knows...!?

[hampton58] 08/1/2019 10:03

+ investor science day in February , CEO , New Chief Medical officer and Tuffts presenting.

[cf456] 08/1/2019 09:50

Multiple potential licence deals anticipated this year.

Given that the recent one with LG Chem was for a potential $310 million, a few of a similar size would be very significant indeed.

And totally dwarf the current market cap of only £37m.

[tomboyb] 08/1/2019 09:43

32p has been broken -

a few more then 34-35p is succession -

Chunky buys helped and has garnered interest -

[bumpa33] 08/1/2019 09:40

No stock available at 32 now. Bids in 50k all around the tracks...

[cf456] 08/1/2019 09:35

Yes, plenty of buying and a few chunkier ones too - 40k and 80k @ 32p.

Interest seems to be picking up.

[bumpa33] 08/1/2019 09:33

Decent buying this morning, full offer price now being paid.

[tomboyb] 08/1/2019 09:32

32p looks like it will break -

[dave4545] 08/1/2019 09:12

TDW no quote to buy

Perhaps the overhang has cleared and this is at 32p offer not 31p

[bumpa33] 08/1/2019 09:08

not convinced we've seen the last of the TR1's, but apart from mild interest in who's come in/who's sold, i'm not that bothered.

[cf456] 08/1/2019 08:51

Here's hoping.

[hampton58] 08/1/2019 08:46

The well known seller is finishedWell known buyer is not !!Post JP Morgan health care conference Momentum will pick up even more

[bumpa33] 08/1/2019 08:46

the 31.5 (advertised) close yesterday was an anomaly. the spread on close was actually 29.4/31.4

[hampton58] 08/1/2019 08:45

31.75 just printed - all buy orders this morning 33-34 by midday

[cf456] 08/1/2019 08:44

There's been a seller offloading in 25k and 50k chunks for a while and that has been holding the price back a bit imo.

If it wasn't for the seller the price would be a lot higher by now.

Plenty of buying coming in though and once the seller clears the price should start motoring.

[hampton58] 08/1/2019 08:43

MM trying to hold the price down , needs stock.The sector is having an explosive re rating on a global scaleNews-flow to accelerate significantly. Watch by midday

[nobbygnome] 08/1/2019 08:21

What can justify the markdown this morning premarket on nothing traded! Yes we don't know what is going on in the background and perhaps there is a big sell order but nevertheless I find it of enormous frustration.

The MMs have a lot to answer for....

[hampton58] 07/1/2019 22:37

What is very clear,the majors are awash in cash and struggling to get a return from their cash cows.Small Bio tech will look even more attractive and in particular with companies in Avacta's area.We will see more news flow and a reaction in the share price and markets applying a different valuation to the company.A huge buy with a lot of momentum building up and interesting shareholder list.

[1i1i1i] 07/1/2019 16:37

31.5p Close, nice ;-)